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Abstract. – OBJECTIVE: COVID‐19, the newly 
emerging infectious disease, has been associ-
ated with acute liver injury, often related to pro-
gression to severe pneumonia. The association 
between moderate-severe liver injury and more 
severe clinical course of COVID-19 has suggest-
ed that liver injury is prevalent in severe than in 
mild cases of COVID-19, while no difference in 
liver involvement has been reported between 
survivors and non-survivors. The spectrum of 
liver involvement during COVID-19 ranges from 
an asymptomatic elevation of liver enzymes to 
severe hepatitis. Only rarely, cases with acute 
hepatitis have been reported in the absence of 
respiratory symptoms. Both epithelial and bil-
iary cells possess the angiotensin-converting 
enzyme-2 receptors that SARS-CoV-2 uses to 
be internalized. However, to our knowledge, no 
ultrastructural identification of the virus in liv-
er cells has been reported to date. Here we pro-
vide evidence of SARS-CoV-2 in the liver of two 
patients, a 34-year-old woman and a 60-year-old 
man with COVID-19.
PATIENTS AND METHODS: We investigated 
two patients with COVID-19 showing several vi-
rions within cytoplasmic vacuoles of cholangio-
cytes and in endothelial cells of hepatic sinu-
soids. In both patients, we performed histologi-
cal and ultrastructural examinations by liver bi-
opsy. After two months, both patients were free 
of symptoms, and the SARS-CoV-2 infection had 
resolved.
RESULTS: Liver biopsy histological and ultra-
structural examination showed liver injury and 
several virions within cytoplasmic vacuoles of 
cholangiocytes and in endothelial cells of he-
patic sinusoids.
CONCLUSIONS: Although most studies in 
COVID-19 have been focused on the lungs, re-
cently, cholestatic liver pathology has been in-
troduced in the spectrum of pathological chang-
es related to COVID-19. To the best of our knowl-
edge, those presented in this paper are the first 
images of hepatic SARS-CoV-2 infected liver 
cells. Our findings suggest a role for cholangio-
cytes and biliary structures in the COVID-19.
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Introduction
Coronavirus disease 2019 (COVID-19) is a 
newly emerging infection disease, declared as a 
global emergency by the World Health Organisa-
tion1.
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In multiple reports worldwide, COVID-19 has 
been associated with acute liver injury (ALI) man-
ifested by increased serum liver enzymes2. Cai 
et al3 focused on liver involvement in patients 
with COVID-19 evidenced abnormal liver func-
tion tests in 3 out of 4 patients, whereas liver 
injury was diagnosed in more than 20% of hospi-
talized patients, often associated with progression 
to severe pneumonia. Phipps et al4 carried out in a 
large cohort of patients affected by COVID-19 and 
focused on the prevalence of acute liver injury in 
carriers of SARS-CoV-2 revealed mild liver injury 
in 45%, moderate in 21%, and severe liver injury in 
6.4%. The latter showed alanine aminotransferase 
(ALT) serum levels > 5 times the upper limit of 
normal, and the majority showed a more severe 
disease course. Patients with severe COVID-19, 
undergoing acute respiratory distress syndrome 
(ARDS), were reported to show higher rates of 
liver injury, when compared with subjects with 
less severe disease5. The association between mod-
erate-severe liver injury and a more severe clinical 
course of COVID-19 was indicated, suggesting 
that liver injury is more prevalent in severe than 
in mild cases of COVID-196. As for the prognostic 
value of liver involvement in COVID-19 patients, 
no difference has been reported between survivors 
and non-survivors7.
The spectrum of liver involvement during CO-
VID-19 ranges from an asymptomatic elevation of 
liver enzymes to severe hepatitis8,4. Epithelial and 
biliary cells possess the angiotensin-converting en-
zyme-2 receptors that severe acute respiratory syn-
drome Coronavirus 2 (SARS-CoV-2) uses to bind to 
cells and to be internalized9. Only rarely, cases with 
acute hepatitis have been reported in the absence 
of respiratory symptoms. In one of these patients, 
transaminase serum levels were detected very high 
(> 20 times normal values), but abnormalities in 
liver function tests quickly normalized10. 
However, to our knowledge, no ultrastructural 
identification of the virus in liver cells has been 
reported to date. Here we provide evidence of 
SARS-CoV-2 virions in the liver of two patients 
who presented during the COVID-19 pandemic 
with signs and symptoms of severe intrahepatic 
cholestasis and underwent a liver biopsy.
Patients and Methods
Electron Microscopy
Electron microscopy examination was per-
formed on the two liver biopsies fixed in glu-
taraldehyde solution in order to search for the 
presence of virus particles suggestive of SARS-
CoV-2 infection.
Genetic Studies
Blood samples of the two patients with SARS-
CoV-2 infection and cholestasis were tested for 
genetic causes of intrahepatic cholestasis. Whole 
exome sequencing was performed focusing on 
a mutational analysis on the 3 main intrahe-
patic cholestasis genes (ATP8B1, ABCB11, and 
ABCB4) and 66 genes causative of genetic syn-




A 34-year-old woman was evaluated for ab-
dominal pain, nausea, jaundice, and pruritus. 
Due to the ongoing COVID-19 pandemic, a 
nasopharyngeal swab was performed, which 
turned positive for SARS-CoV-2 infection; so, 
the patient was admitted to a dedicated unit. 
Abdominal ultrasound and magnetic resonance 
cholangiopancreatography (MRCP) excluded 
biliary duct dilation and signs of chronic liver 
disease. Nevertheless, two endoscopic cholangi-
opancreatographies were performed, and a small 
stone was removed from the extrahepatic biliary 
duct. Due to worsening cholestasis, a decision 
was thus made to obtain a percutaneous liver 
biopsy. Histological examination showed mild 
bilirubin accumulation within biliary canaliculi 
and in the cytoplasm of Kupffer cells. Neutro-
phils were seen in sinusoids and scanty lym-
phocytes in portal spaces. Electron microscopy 
findings are shown in Figure 1, Panels A-D. The 
patient tested negative for the 3 main intrahepat-
ic cholestasis genes, while was heterozygous for 
a known pathogenetic mutation (c.964-1G>C) in 
the DHCR7 (dehydrocholesterol reductase) gene 
responsible for Lemli-Opitz syndrome (MIM 
270400).
Case 2
A sixty-year-old man became severely jaun-
diced and symptomatic for pruritus two weeks 
after having suspended the use of a gym supple-
ment (LGD-4033; Ligandrol®; Ligand Pharma-
ceuticals Incorporated, San Diego, CA, USA) 
capsules, that he had been consuming in the pre-
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ceding four weeks. He had stopped taking the 
capsules because he had noticed that the urine 
was strongly colored. A MRCP did not demon-
strate abnormalities of the biliary tree. A deci-
sion was made to admit him as an in-patient for 
a percutaneous liver biopsy while whole exome 
sequencing results were pending; due to the 
cautionary rules adopted in the hospital during 
the ongoing COVID-19 pandemic, he underwent 
two nasopharyngeal swabs, one of which turned 
positive for SARS-CoV-2 infection. Liver biopsy 
showed bile plugs in dilated canaliculi, mostly 
in perivenular location, without cholestatic ro-
settes and only mild infiltration of neutrophilic 
and lymphocytes in sinusoids and portal spaces. 
Electron microscopy findings are shown in Fig-
ure 1, Panels E-F. Genetic studies showed that 
the patient carried a heterozygous pathogenetic 
mutation (p.Ser320Phe) in the ATP binding cas-
sette subfamily B member 4 (ABCB4) gene, 
previously described in compound heterozygous 
patients with progressive familial intrahepatic 
cholestasis, in heterozygous patients with intra-
hepatic cholestasis of pregnancy (MIM 614972), 
drug-induced cholestasis, low phospholipid-as-
sociated cholelithiasis (MIM 600803).
Course
The course of liver biochemistry for both cases 
is presented in Table I. Two months after the liver 
biopsy, both patients were free of symptoms of 
cholestasis, and Sars-CoV-2 infection had re-
solved.
Discussion
Although most studies in COVID-19 have been 
focused on the lungs, recently, liver pathology has 
been introduced in the spectrum of pathological 
changes related to COVID-192. The histological 
liver changes appear unspecific, mainly char-
acterized by microvesicular steatosis11. Previous 
electron microscopic studies evidenced the pres-
ence of SARS-CoV-2 in human airway epithelial 
cells12. SARS-CoV-2 particles were detected in 
Figure 1. Electron microscopy evidence of SARS-CoV-2 infection in liver cells. Case 1, A-D. Cholangiocyte showing several 
virions within cytoplasmic vacuoles, lining the plasmalemma and within the biliary lumen (arrows). Virus-like particles were 
also observed within the perinuclear cisternae (arrow, B). The mature virions, about 60-85 nm in diameter, were composed of 
an inner and an outer part. The inner part was usually electron-lucent with variable amounts of peripheral granular electron-
dense material, corresponding to the sections of the nucleocapsid. The outer part consisted of a lipidic envelope with club-like 
structures or “spikes” about 15-20 nm long. Note an image of budding (arrow, D). Original magnification: A, 7000×; B, D, 
85000×; C, 50000×. Case 2, E-F. A virus-like particle of about 80 nm, with spikes, within a cisterna of rough endoplasmic 
reticulum, in an endothelial cell of hepatic sinusoids. Original magnification: E, 3000×; F, 20000×.
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lung tissue by transmission electron microscopy, 
appearing enclosed in single-membrane vacu-
oles13. Coronavirus-like particles were detected 
in the respiratory system, kidney and gastroin-
testinal tract14. Electron microscopy of kidney 
biopsies from a patient affected by COVID-19 
showed the presence of viral inclusion bodies in 
endothelial cells. Viral particles were observed in 
peritubular spaces of endothelial cells of the glo-
merular capillaries. Aggregates of viral particles 
were characterized by a dense circular surface 
and a lucid center15. The size of coronaviruses 
has been reported to range between about 80 
and 140 nm16. Accordingly with what was ob-
served in a SARS patient by Goldsmith et al17 in 
2004, virions showed spherical shape, 78 nm in 
mean diameter, and were composed of a helical 
nucleocapsid within an envelope with surface 
projections.
To the best of our knowledge, those presented 
in this paper are the first images of hepatic 
SARS-CoV-2 infected cells, detecting that the 
liver is a target for this virus. Moreover, the 
present report adds to the fast-growing literature 
on COVID-19 the suggestion that SARS-CoV-2 
infection, temporally related to intrahepatic cho-
lestasis, may occasionally favor its development 
in the presence of other cofactors. Gene vari-
ants of ABCB4, coding for a glycoprotein also 
known as multidrug resistance protein 3, have 
indeed been associated with the full spectrum 
of cholestatic diseases, with low, normal or high 
glutamyltranspeptidase18. Regarding the DHCR7 
mutation detected in Case 1, the mutation impairs 
the DHCR7 protein expression severely, but no 
clinical manifestations in heterozygous carries 
have been reported yet19. Therefore, in our cases, 
biliary lithiasis may have played a role.
Conclusions
Based on recent literature, COVID-19 appears 
a complex systemic disease triggering multiple 
molecular pathways in different organs20. Mul-
tiple recent works have highlighted the putative 
role of liver involvement in the physiopathol-
ogy and outcome of infection by SARS-CoV-2, 
suggesting a peculiar “hepatic tropism” for this 
virus21. The two described cases confirm the 
hypothesis of a putative central role of the liver 
in the pathophysiology of COVID-19. The find-
ing of viral structures in cholangiocytes is the 
first evidence of SARS-CoV-2 cholangiocellular 
infection so far reported in COVID-19 patients. 
Our outcomes confirm previous data in human 
liver ductal organoid cultures in which, follow-
ing SARS-CoV-2 infection, cholangiocytes un-
derwent pathological changes22. Moreover, our 
results reinforce the significance of the one case 
report of SARS-CoV-2 RNA in bile23 and con-
firm the hypothesis that the gut-liver-bile-gut 
axis might represent a vicious circle which might 
increase the chances of survival for the virus21. 
Table I. Time course of liver biochemistry tests.
 At presentation At the time of liver biopsy At last follow-up visit
Case 1 
AST, U/l   43   80   60 
ALT, U/l  102  148   82 
ALP, U/l  441  391  417 
GGT, U/l   68   18   23 
Bilirubin, mg/dl 
  Total  6.2 15.6 2.7
  Direct  5.2  13.0  2.1 
Case 2 
AST, U/l   90   64   44 
ALT, U/l  254   75   44 
ALP, U/l  NA  440  277 
GGT, U/l   24   23   24 
Bilirubin, mg/dl 
  Total  17.0 11.3 3.2
  Direct  12.7   9.0  2.6 
ALT (alanine aminotransferase): normal range 0-40 U/l; AST (aspartate aminotransferase): normal range 0-40 U/l; ALP (alkaline 
phosphatase): normal range 70-290 U/l (female), 90-360 U/l (male); GGT (gamma-glutamyl transferase): normal range 0-50 U/l. 
Total bilirubin: 0.3-1.2 mg/dl.
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Many crucial questions remain open regarding 
the role of liver involvement in COVID-19 pa-
tients. Our findings suggest a role for cholangio-
cytes and biliary structures in this disease. Future 
research on the role of the liver in COVID-19 is 
needed to set up more appropriate therapeutic and 
preventive programs regarding liver involvement. 
In particular, patients like those here reported, 
with cholestatic features and with signs of dam-
age of the biliary epithelium, should undergo 
long-term hepatic follow-up in order to prevent 
the insurgence of secondary sclerosing cholan-
gitis (SSC) previously described in critically ill 
patients (CIP)24.
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